D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1
R Zhang, Y Yang, W Dong, M Lin… - Proceedings of the …, 2022 - National Acad Sciences
Breast cancer is the most frequent malignancy in women worldwide, and triple-negative
breast cancer (TNBC) patients have the worst prognosis and highest risk of recurrence. The …
breast cancer (TNBC) patients have the worst prognosis and highest risk of recurrence. The …
[HTML][HTML] Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer
Triple-negative breast cancer (TNBC), the most difficult-to-treat breast cancer subtype, lacks
well-defined molecular targets. TNBC has increased programmed death-ligand 1 (PD-L1) …
well-defined molecular targets. TNBC has increased programmed death-ligand 1 (PD-L1) …
Guanosine diphosphate–mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer
JH Ding, Y Xiao, F Yang, XQ Song, Y Xu… - Science Translational …, 2024 - science.org
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with
poor prognosis. TNBCs with high homologous recombination deficiency (HRD) scores …
poor prognosis. TNBCs with high homologous recombination deficiency (HRD) scores …
[HTML][HTML] Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1
Protein glycosylation provides proteomic diversity in regulating protein localization, stability,
and activity; it remains largely unknown whether the sugar moiety contributes to …
and activity; it remains largely unknown whether the sugar moiety contributes to …
[HTML][HTML] D-mannose suppresses macrophage IL-1β production
S Torretta, A Scagliola, L Ricci, F Mainini… - Nature …, 2020 - nature.com
D-mannose is a monosaccharide approximately a hundred times less abundant than
glucose in human blood. Previous studies demonstrated that supraphysiological levels of D …
glucose in human blood. Previous studies demonstrated that supraphysiological levels of D …
Combination of chidamide-mediated epigenetic modulation with immunotherapy: Boosting tumor immunogenicity and response to PD-1/PD-L1 blockade
K Tu, Y Yu, Y Wang, T Yang, Q Hu, X Qin… - … applied materials & …, 2021 - ACS Publications
Improving tumor immunogenicity is critical for increasing the responsiveness of triple-
negative breast cancer (TNBC) to anti-PD-(L) 1 treatment. Here, we verified that chidamide …
negative breast cancer (TNBC) to anti-PD-(L) 1 treatment. Here, we verified that chidamide …
Palmitoylation stabilizes PD-L1 to promote breast tumor growth
Dear Editor, PD-L1 is a well-known transmembrane protein, which is highly expressed on
many types of cancer cells. By binding to its receptor PD-1 on T cells, PD-L1 significantly …
many types of cancer cells. By binding to its receptor PD-1 on T cells, PD-L1 significantly …
PD-L1 expression in triple-negative breast cancer
EA Mittendorf, AV Philips, F Meric-Bernstam… - Cancer immunology …, 2014 - AACR
Early-phase trials targeting the T-cell inhibitory molecule programmed cell death ligand 1
(PD-L1) have shown clinical efficacy in cancer. This study was undertaken to determine …
(PD-L1) have shown clinical efficacy in cancer. This study was undertaken to determine …
[HTML][HTML] PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer
C Chen, S Li, J Xue, M Qi, X Liu, Y Huang, J Hu… - JCI insight, 2021 - ncbi.nlm.nih.gov
Although the immune checkpoint role of programmed death ligand 1 (PD-L1) has been
established and targeted in cancer immunotherapy, the tumor-intrinsic role of PD-L1 is less …
established and targeted in cancer immunotherapy, the tumor-intrinsic role of PD-L1 is less …
[HTML][HTML] Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
Y Tang, S Wang, Y Li, C Yuan, J Zhang, Z Xu… - Journal of …, 2022 - Springer
Blockade of programmed cell death 1 ligand (PD-L1) has been used to treat triple-negative
breast cancer (TNBC), and various strategies are under investigation to improve the …
breast cancer (TNBC), and various strategies are under investigation to improve the …